Inavolisib用于乳腺癌的III 期研究｜NCT06790693

一分钟看懂

这是一项关于乳腺癌的III 期研究，登记的药物或干预包括Inavolisib；Placebo；CDK4/6i；Letrozole，当前状态为招募中。登记地点显示中国襄阳、北京、长沙、成都等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。

Inavolisib；Placebo；CDK4/6i；Letrozole · III 期

年龄范围：18岁及以上

登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。

登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。

以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。

以下为摘录，请打开原始登记查看完整入排标准。

* Women or men with histologically or cytologically confirmed carcinoma of the breast
* Documented ER-positive and/or progesterone receptor-positive tumor according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines
* Documented HER2-negative tumor according to ASCO/CAP guidelines
* De-novo HR+ , HER2- ABC, or, alternatively, relapsed HR+ , HER2- ABC after at least 2 years of standard neoadjuvant/adjuvant endocrine therapy without disease progression during that treatment and disease-free interval of at least 1 year since the completion of that treatment
* Participants who have bilateral breast cancers which are both HR-positive and HER2-negative
* Confirmation of biomarker eligibility
* Consent to provide fresh or archival tumor tissue specimen
* Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。

登记号：NCT06790693；登记信息更新于 2026-10-06；本站同步于 2026-10-08，中国中心当前名额未经人工确认。